David Shaw’s Aprea Therapeutics APRE Stock Holding History

David Shaw’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,488	Closed	-$37K	–	5163
2022 Q2	$37K	Buy	2,488 +1,644	+195%	+$37.9K	﹤0.01%	4896
2022 Q1	$31K	Buy	+844	New	+$34.6K	﹤0.01%	5259

Other funds holding APRE

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

David Shaw's APRE Position: Q3 2022 in Review

David Shaw sold out of Aprea Therapeutics (APRE) in Q3 2022, closing a stake of 2,488 shares — an estimated $37K sold.

David Shaw first reported a position in APRE in Q1 2022 and held it in 2 quarters. The position peaked at $37K in Q2 2022. 26 funds tracked by Wall St. Rank hold APRE as of Q3 2022.

David Shaw reported no remaining Aprea Therapeutics position as of Q3 2022 after selling out during the quarter.
David Shaw sold 2,488 Aprea Therapeutics shares in Q3 2022, an estimated $37K.
David Shaw first reported a position in Aprea Therapeutics in Q1 2022 and held it in 2 quarters.
David Shaw's Aprea Therapeutics position peaked at $37K in Q2 2022.
26 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.